Dive Brief:
The commercial progress for so-called autologous CAR-T treatments, which genetically alter a patient's immune cells to find and kill cancers, has been slow to develop. The drugs are only approved for certain blood cancer patients who have essentially run out of options. Even then, they are hampered by logistical challenges such as a multi-week manufacturing and delivery process.
Though sales of Kymriah, for instance, grew 19% to $147 million last quarter, the "overall demand in the class has slowed down," said Susanne Schaffert, the president of Novartis' oncology division, on an earnings call. Revenues are well short of the blockbuster numbers the drugmakerinitially envisioned.
The field's top developers Novartis, Gilead and Bristol Myers Squibb hope to change the narrative by bringing their treatments to earlier lines of care, a larger market opportunity. Each company has launched trials testing their treatments in second-line settings in lymphoma, where they're aiming to show CAR-T is better than chemotherapy and transplants at holding patients' disease in check.
Even if successful, the drugmakers will face challenges. While the combination of chemo and transplants often isn't curative and causes several side effects, CAR-T treatments are also associated with toxicities most notably, neurological and immune-related problems and are limited mostly to academic centers.
Nonetheless, prior to Novartis' announcement, the early returns had been encouraging. In June, for instance, Bristol Myers said treatment with its cell therapy Breyanzi resulted in a "clinically meaningful and highly statistically significant" improvement over standard care in patients with large B-cell lymphoma. Gilead immediately followed with a similar result for its treatment, Yescarta, along with plans to begin discussions with regulators.
Those two have now separated themselves from Novartis. The results disclosed by the drugmaker Tuesday come from the BELINDA trial, which tested Kymriah in 355 patients with aggressive B-cell non-Hodgkin lymphoma who either hadn't responded to first-line care or relapsed within a year. Novartis only revealed that Kymriah missed its primary goal, which was an improvement in the time to the first documented progression of disease, or death, at least 12 weeks after treatment. The company didn't say how Kymriah fared on secondary measures, such as the percentage of patients who responded or how long treatment effects appeared to last.
"The study investigators will work together with Novartis in the coming weeks and months to understand the factors that contributed to this outcome," said Michael Bishop, the chair of the study's steering committee and Director of the Hematopoietic Stem Cell Transplantation Program at University of Chicago Medicine, in a statement.
Kymriah is approved for acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Novartis plans to submit an application for use in follicular lymphoma later this year.
Read this article:
Novartis falls behind rivals in race to bring CAR-T to early lymphoma - BioPharma Dive
- World's first diabetes cure with cell therapy achieved in China - Interesting Engineering - May 27th, 2024
- Illustration of stress buildup [IMAGE] - EurekAlert - May 27th, 2024
- U.S. Induced Pluripotent Stem Cell (iPSC) Market Anticipated to Climb to USD 1,372.22 Million by 2032, with... - WhaTech - May 25th, 2024
- City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art ... - Elk Valley Times - May 25th, 2024
- Aspen wins grant to advance stem cell therapy for Parkinson's disease - Parkinson's News Today - May 23rd, 2024
- Fort Lauderdale woman says she paid over $14K for stem cell injections that did not cure arthritis - WSVN 7News | Miami News, Weather, Sports | Fort... - May 23rd, 2024
- Benefits of Stem Cell Therapy: Unlocking Regenerative Medicine's Potential - Intelligent Living - May 23rd, 2024
- The rapid progression of sepsi [IMAGE] - EurekAlert - May 18th, 2024
- Sketchy stem-cell treatments in Mexico led to drug-resistant infections - Livescience.com - May 15th, 2024
- Analytical Considerations for Gene-Modified Hematopoietic Stem and Progenitor Cell Therapies: Part 1 In-Process ... - BioProcess Insider - May 15th, 2024
- Innovative 'mini-brains' could revolutionize Alzheimer's diagnosis and treatment - News-Medical.Net - May 15th, 2024
- Cell Therapy Market size is set to grow by USD 31041.49 million from 2023-2027, limitations in traditional organ ... - The Malaysian Reserve - May 15th, 2024
- Notes from the Field: Potential Outbreak of Extrapulmonary ... - CDC - May 13th, 2024
- Yale Cancer Center Earns International Reaccreditation for Expertise in CAR T-cell Therapy and Stem Cell ... - Yale School of Medicine - May 10th, 2024
- Stem Cell Therapy Improves Post-Stroke Motor Function - Medscape - May 10th, 2024
- Ozzy Osbourne receiving stem cell treatments amid health problems - The Star Online - May 10th, 2024
- How hematopoietic stem cells retain their regenerative potential - Drug Target Review - May 10th, 2024
- First Patient Begins Newly Approved Sickle Cell Gene Therapy - The New York Times - May 8th, 2024
- Advances and challenges of the cell-based therapies among diabetic patients - Journal of Translational Medicine - Journal of Translational Medicine - May 8th, 2024
- Stem Cell Therapy market impeccable growth with a CAGR of 18.9% during 2023-2029 - openPR - May 8th, 2024
- Stem Cells market to be at USD 5673.4 million by 2029 with a CAGR of 10.4% during 2023-2029 - openPR - May 8th, 2024
- "Charting the Course: Global Animal Stem Cell Therapy Market - openPR - May 8th, 2024
- Stanford stem cell researcher who discovered how to regrow cartilage, dies at 48 - Redwood City Pulse - May 6th, 2024
- Chuck Chan, stem cell researcher who discovered how to regrow cartilage, dies at 48 - Palo Alto Online - May 4th, 2024
- Stem Cell and Platelet Rich Plasma Alopecia Therapies Market Analysis and Future Outlook by 2030 - openPR - May 4th, 2024
- Opinion: As stem cell biologists, we're concerned a Utah law will lead to a boom in snake oil sales - Salt Lake Tribune - May 2nd, 2024
- Robert Hariri: Developing Cost-Effective Cell Therapies From Placentas - BioSpace - May 2nd, 2024
- USC-led study introduces a new and improved way to grow the cells that give rise to the kidney's filtration system - EurekAlert - May 2nd, 2024
- Using stem cell-derived heart muscle cells to advance heart regenerative therapy - Medical Xpress - April 28th, 2024
- John Cleese is spending thousands on stem cell therapy is it really the secret to anti-ageing? - Yahoo Lifestyle Australia - April 28th, 2024
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
Recent Comments